MB-102

DRUG4 trials

Sponsors

MediBeacon, Mustang Bio

Conditions

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Chronic Kidney DiseaseCrohn DiseaseKidney DiseasesKidney FailureKidney Injury

Early Phase 1

Oral Administration of MB-102 Versus Dual Sugar Testing for Gut Permeability

CompletedNCT03962998

MediBeaconCrohn Disease

Start: 2019-10-27End: 2021-10-05Updated: 2022-06-10

Phase 1

Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.

TerminatedNCT04109482

Mustang BioBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Start: 2020-02-17End: 2023-05-17Updated: 2024-07-22

Phase 3

Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects

CompletedNCT05425719

MediBeaconChronic Kidney Disease

Start: 2022-06-14End: 2023-02-15Updated: 2024-04-18

Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring

CompletedNCT05777174

MediBeaconKidney Diseases, Kidney Failure, Kidney Injury

Start: 2023-03-20End: 2024-04-15Updated: 2025-03-28

Related Papers

Novel Targeted Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm

Oncology Times2019-12-24